Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IRON | US
3.05
4.99%
Healthcare
Biotechnology
30/06/2024
09/03/2026
64.23
62.29
67.15
61.58
Disc Medicine Opco Inc together with its subsidiaries operates as a clinical-stage biotechnology company engages in the discovery development and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company builds a portfolio of fundamental biological pathways of red blood cell biology primarily heme biosynthesis and iron homeostasis. It also develops bitopertin for the treatment of erythropoietic porphyrias erythropoietic protoporphyria and X-linked protoporphyria. In addition the company develops DISC-0974 for the treatment of chronic kidney disease; MWTX-003 for the treatment of polycythemia vera and other hematologic disorders; and DISC-0998 for the treatment of anemia associated with inflammatory. The company is based in Watertown Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
50.1%1 month
112.6%3 months
76.2%6 months
66.0%-
-
3.07
0.00
0.00
-7.56
-
-
-110.80M
1.91B
1.91B
-
-
-
-
-21.16
8.00
6.08
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
10.47
Range1M
39.80
Range3M
59.50
Rel. volume
0.90
Price X volume
61.25M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals Inc. Common Stock | DAWN | Biotechnology | 21.33 | 2.10B | 0.61% | n/a | 0.06% |
| Ultragenyx Pharmaceutical Inc | RARE | Biotechnology | 22.61 | 2.08B | 6.40% | n/a | 214.27% |
| Aurinia Pharmaceuticals Inc | AUPH | Biotechnology | 14.37 | 2.05B | 0.35% | n/a | 23.58% |
| STROUDS INC | STRO | Biotechnology | 24.98 | 2.05B | -1.23% | n/a | 125.14% |
| Celldex Therapeutics Inc | CLDX | Biotechnology | 30.73 | 2.04B | 4.42% | n/a | 0.29% |
| Syndax Pharmaceuticals Inc | SNDX | Biotechnology | 23.88 | 2.03B | 8.20% | n/a | 0.26% |
| Wave Life Sciences Ltd | WVE | Biotechnology | 13.29 | 2.02B | 1.30% | n/a | 656.70% |
| Stoke Therapeutics Inc | STOK | Biotechnology | 38.31 | 2.02B | 7.98% | n/a | 2.40% |
| Tonix Pharmaceuticals Holding Corp | TNXP | Biotechnology | 13.94 | 1.95B | 3.64% | n/a | 21.99% |
| Zai Lab Limited | ZLAB | Biotechnology | 19.12 | 1.94B | -2.15% | n/a | 11.88% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| HNI Corporation | HNI | Building Products & Equipment | 41.37 | 1.95B | -0.17% | 22.12 | 76.47% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 10.67 | 1.92B | 0.85% | n/a | -571.93% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.07 | 1.41B | 1.22% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 36.22 | 1.14B | 1.06% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 35.25 | 1.02B | -2.87% | 22.53 | 56.33% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.39 | 783.29M | 1.89% | 11.62 | 116.21% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.31 | 729.29M | 0.16% | 65.18 | 77.00% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 16.37 | 682.35M | 0.37% | 42.05 | 64.69% |
| Ennis Inc | EBF | Building Products & Equipment | 21.16 | 550.24M | -0.70% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 25.67 | 513.16M | -0.39% | n/a | 1.50% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -7.56 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.07 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 76.25 | 72.80 | Par |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 1.91B | 3.66B | Emerging |